Figure 30

![Figure 30: Emerging phytocannabinoid formulations for epilepsy include transdermal, intranasal, and sublingual delivery systems. Alternative routes of administration may improve bioavailability and reduce gastrointestinal side effects.]()

> Source: Lara Senn et al. "Receptors and Channels Possibly Mediating the Effects of Phytocannabinoids on Se." *Pharmaceuticals (Basel, Switzerland)*, 2020. PMID: [32751761](https://pubmed.ncbi.nlm.nih.gov/32751761/)

<figure>
  <img src="" alt="Emerging phytocannabinoid formulations for epilepsy include transdermal, intranasal, and sublingual delivery systems. Alternative routes of administration may improve bioavailability and reduce gastrointestinal side effects." />
  <figcaption>Figure 30. Emerging phytocannabinoid formulations for epilepsy include transdermal, intranasal, and sublingual delivery systems. Alternative routes of administration may improve bioavailability and reduce gastrointestinal side effects.<br>  Source: Lara Senn et al. "Receptors and Channels Possibly Mediating the Effects of Phytocannabinoids on Se." <em>Pharmaceuticals (Basel, Switzerland)</em>, 2020. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/32751761/">32751761</a></figcaption>
</figure>